Key facts
- It has raised $16.6M; the latest was Early Stage VC ($15.1M) in Jan 2025.
- Notable investors include Qiming Venture Partners, China Growth Capital, Insight Capital (Taicang), Jiangbei Investment Group, THG Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Iongen Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Iongen Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Iongen Therapeutics
Developer of innovative pain treatment drugs designed for targeting sodium ion channels Nav1.8 and Nav1.7. The company focuses on advancing novel analgesic solutions, providing cutting-edge drug research and development for pain management.
- Sector
- Healthcare
- HQ
- Nanjing, China
- Founded
- 2021
- Website
- iongentherapeutics.com/
- Ownership
- Privately Held (backing)
Iongen Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Iongen Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Iongen Therapeutics in its N-PORT filings yet. We sweep new filings monthly.